Fibralign Corporation

Info

Contact Greg King

Title CEO

Description

Fibralign’s first product BioBridge is developed to address Secondary Lymphedema, a global chronic debilitating disease that affects over 120M people and has no cure (World Health Org, other sources). The Company successfully completed a large animal study with Stanford (DoD funded) that validated BioBridge treated diseased lymphatic tissue. Fibralign is now preparing for 510(k) submission and a clinical study with Stanford. Fibralign has a strong IP position (11 patents, 14 pending) and a scalable manufacturing process for making this and other devices.

Company News

Fibralign Announces Start of European Lymphedema Prevention Clinical Study

DateFeb 9, 2021

Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first patient in a multi-site, randomized clinical trial in Europe evaluating its BioBridge® Collagen Matrix as a novel preventative treatment for secondary lymphedema.

Fibralign Announces CE Mark Approval for BioBridge

DateSep 14, 2020

Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first product, the BioBridge® Collagen Matrix.

Fibralign Announces Strategic Partnership With Terumo

DateJun 2, 2020

Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced today that it has executed a long term distributor agreement with Terumo Corporation to market and distribute the BioBridge® Collagen Matrix in Japan for treating and preventing secondary lymphedema.

Fibralign and MedTech Innovator Featured in General Surgery News

DateFeb 13, 2017

The prizes valued at $150,000 awarded to the company that won the 2014 MedTech Innovator competition were nothing to sneeze at; but just as important, if not more so, were the support and exposure the startup received as participants of MTI’s accelerator program.

Fibralign announces enrollment initiated for Stanford-led clinical trial for breast cancer-related Lymphedema

DateSep 1, 2016

Fibralign beats 267 other startups at the 2014 MedTech Innovator competition

DateJul 14, 2014

The Biobridge is an implant that has been shown to be able to guide the growth of new lymph channels. This technology can be used as an adjunct to existing treatments for the condition to hopefully improve outcomes. Fibralign has benefited from grants from the DoD and NSF to support a large animal study and develop production tools for making its initial product.